Pelthos Therapeutics Inc.
Pelthos Therapeutics Inc. is a U.S.-based biopharmaceutical company focused on developing and commercializing prescription therapies. Its business is organized around pharmaceutical products and related intellectual property, with operations structured through corporate transactions and licensing arrangements in the United States.
Fiscal year 2025 · change from previous year
Development 2022–2025
Business
Share of revenueDrug products intended for prescription use and commercial sale.
Development activities supporting clinical, regulatory, and commercial readiness.
Acquisition, assignment, and monetization of pharmaceutical IP rights.
Transactions and agreements that support external commercialization of assets.
Products
Reported · share of revenue- Net Product96.5 %
- License and Collaboration3.5 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Pelthos serves patients through prescription drug products, but its direct commercial counterparties can also include distributors, licensees, and strategic partners involved in development or commercialization. In a biopharmaceutical model like this, demand is driven by physician prescribing, payer access, and the ability to secure regulatory and commercial pathways for specific therapies.
End users and clinicians who drive demand for prescription therapeutics.
Channel partners that purchase or distribute pharmaceutical products.
Counterparties in IP, asset transfer, and commercialization agreements.
Organizations that affect access, pricing, and uptake of therapies.
Strategy
Pelthos appears focused on building value through pharmaceutical asset development, commercialization, and partnering transactions. The disclosed agreements suggest a strategy centered on securing capital, aligning with strategic counterparties, and advancing the company’s therapeutic portfolio through corporate and IP transactions.
Drug assets only create value if they reach patients through approved and reimbursed channels.
IP assignments and licensing can provide capital and strategic flexibility.
Biopharmaceutical development typically requires external funding before product cash flow is established.
Geography
Pelthos is headquartered in the United States and its disclosed corporate activity is centered there. The available filings do not provide a country-by-country revenue split, so the business profile should be viewed as U.S.-anchored with exposure to U.S. healthcare regulation, commercialization, and capital markets.
Risks
Pelthos faces the typical risks of a small biopharmaceutical company: clinical, regulatory, commercialization, and financing uncertainty. Its filings also show dependence on external transactions and equity funding, which can create dilution, execution risk, and sensitivity to capital market conditions.
- Financing and dilution riskImpact: HighLikelihood: Medium
The company has relied on PIPE financing and equity issuance to fund operations and transactions.
Exposure: Common stock and preferred stock financing
- Regulatory and commercialization riskImpact: High
Prescription therapeutics depend on regulatory clearance, market access, and physician adoption.
Exposure: Drug assets and commercialization efforts
- Execution risk in transactionsImpact: MediumLikelihood: High
Corporate, licensing, and IP agreements must be completed and integrated successfully to create value.
Exposure: Merger-related and IP-related agreements
- Asset concentration riskImpact: Medium
Smaller biopharma companies often depend on a limited number of programs or rights.
Exposure: Therapeutic portfolio and IP assets
Accounting
Judgemental itemsConvertible or redeemable equity instruments may require fair value or mezzanine classification judgments.
Impact: Can materially affect balance sheet presentation and earnings volatility
Pharmaceutical IP and development assets require judgmental valuation and periodic impairment review.
Impact: Can drive non-cash charges if asset values change
PIPE financing and merger-related issuances affect share count, APIC, and dilution.
Impact: Impacts EPS, equity balances, and ownership structure
Similar listed companies
Publicly listed companies with a comparable business focus.
Provectus Biopharmaceuticals, Inc.
PVCT · Pharmaceutical Preparations
Cero Therapeutics Holdings, Inc.
CEROW · Biological Products, (No Diagnostic Substances)
Curanex Pharmaceuticals Inc
CURX · Pharmaceutical Preparations
Curanex Pharmaceuticals Inc is a U.S.-based pharmaceutical preparations company that appears to be in an early-stage, development-focused phase.
Kairos Pharma, LTD.
KAPA · Pharmaceutical Preparations
Liminatus Pharma, Inc.
LIMNW · Biological Products, (No Diagnostic Substances)
Terns Pharmaceuticals, Inc.
Pharmaceutical Preparations
Last updated: 24/09/2026